France Chronic Myelogenous Leukemia Therapeutics Market Report 2022 to 2030

France Chronic Myelogenous Leukemia Therapeutics Market Analysis

$ 3999

France Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.

ID: IN10FRRD015 CATEGORY: Rare Diseases GEOGRAPHY: France AUTHOR: Nipun Arora

Buy Now

France Chronic Myelogenous Leukemia Therapeutics Market Analysis Summary

France Chronic Myelogenous Leukemia Therapeutics Market is valued at around $0.42 Bn in 2022 and is projected to reach $0.66 Bn by 2030, exhibiting a CAGR of 5.8% during the forecast period 2023-2030.

A rare kind of cancer of the bone marrow, the spongy tissue found inside bones where blood cells are formed, is chronic myelogenous leukaemia (CML). The amount of white blood cells in the blood rises as a result of CML. In contrast to acute forms of leukaemia, which tend to advance more quickly, chronic myelogenous leukaemia tends to advance more slowly. In chronic myelogenous leukaemia, the word "myelogenous" refers to the type of cells that are impacted by this malignancy. Other names for chronic myelogenous leukaemia include chronic granulocytic leukaemia and chronic myeloid leukaemia.

In CML, an excessive number of blood stem cells develop into granulocytes, a kind of white blood cell. Due to their abnormality, these granulocytes do not develop into normal white blood cells. They go by the name leukemia cells as well. There may be an accumulation of leukemia cells in the blood and bone marrow, leaving less space for normal white blood cells, red blood cells, and platelets. Infection, anaemia, or simple bleeding could result from this. When a person has chronic myelogenous leukemia, their blood cells' chromosomes swap portions with one another. An extra-short chromosome 22 and an extra-long chromosome 9 are created when a portion of chromosome 9 swaps places with a section of chromosome 22. The Philadelphia chromosome, so named for the location of its discovery, is a very short chromosome 22. Ninety percent of patients with chronic myelogenous leukemia have Philadelphia chromosomes in their blood cells. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come.

Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.

Market dynamics

Market Drivers

The market is anticipated to be driven by a growth in the number of elderly people, higher medication approval rates, the designation of acute myeloid leukaemia as an orphan disease, and rising healthcare costs. One of the factors influencing market expansion is the technological progress gained in identifying damaged cells.

Market Developments

Treatment for Chronic Myeloid Leukemia (CML) has advanced significantly in recent years. Tyrosine kinase inhibitors (TKIs) have been shown to dramatically enhance patient outcomes when used as frontline therapy. The creation of new TKIs with greater selectivity and fewer side effects has helped the market expand. Patients who are intolerant or resistant to TKIs now have access to alternate therapeutic alternatives such as bone marrow transplantation and new immunotherapy medications. For Chronic Myelocytic Leukemia, MedPacto is currently in Phase II of its clinical development of vactosertib (CML, Chronic Myeloid Leukemia).

According to Novartis, the FDA has approved Scemblix, also known as asciminib, for patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) who have used at least two prior tyrosine kinase inhibitors (TKIs) and have the T315I mutation. In a phase 3 chronic myeloid leukemia (CML) research, Novartis' asciminib outperformed Pfizer's Bosulif, bringing it one step closer to gaining clearance for a candidate meant to combat treatment intolerance and resistance.

To treat adult patients with chronic or accelerated chronic myeloid leukemia in China, Ascentage Pharma introduced Olverembatinib in December 2021. (CML). The first drug of its sort to be produced in China is called olverembatinib, and it is made by Guangzhou HealthQuest Pharma Co Ltd Inc, a fully-owned subsidiary of Ascentage Pharma.

Key players

Novartis AbbVie Genentech Roche Gilead Sciences Bristol-Myers Squibb Johnson & Johnson Celgene Pfizer BMS

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market segmentations for France Chronic Myelogenous Leukemia Therapeutics market

By treatment options

Targeted therapy
Chemotherapy
Radiation therapy
Splenectomy
Stem cell transplant
Others

By Chemotherapy

Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy

By Regimen

DC Regimen
AVD Regimen
VCD Regimen

By End-User

Hospital
Retails Drug Stores
Ambulatory Care Centers
Clinics

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.